Status:
TERMINATED
Fexofenadine Use in Gastroesophageal Reflux Symptoms
Lead Sponsor:
Stanford University
Conditions:
Gastroesophageal Reflux
Eligibility:
All Genders
18-90 years
Phase:
PHASE2
Brief Summary
The investigators wish to study the effectiveness of Fexofenadine (an over the counter allergy pill) for the treatment of gastroesophageal reflux symptoms in patients who still have symptoms despite b...
Detailed Description
Around 18-28% of North American adults have gastroesophageal reflux symptoms once per week. Of those patients up to 60% may have an inadequate response to proton pump inhibitors and have persistent sy...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- A minimum 6-month history of heartburn and regurgitation, as their main symptom
- Experience at least 3-4 days with episodes of heartburn or regurgitation per week
- Female patients who are postmenopausal or using acceptable methods of birth control.
- Exclusion Criteria (selected)
- Esophageal stricture
- Primary esophageal motility disorder
- Systemic sclerosis
- Active inflammatory bowel disease
- Zollinger-Ellison syndrome
- Active gastric or duodenal ulcer
- Active infectious or inflammatory conditions of the small or large intestine
- Malabsorption syndromes of the intestine
- History of gastrointestinal cancer
- Current active cancer
- Prior gastric or intestinal surgery
- Pregnant or breast feeding
- Other serious psychiatric or medical disease
Exclusion
Key Trial Info
Start Date :
February 7 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 8 2019
Estimated Enrollment :
11 Patients enrolled
Trial Details
Trial ID
NCT03425097
Start Date
February 7 2018
End Date
January 8 2019
Last Update
February 17 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford Health Care
Redwood City, California, United States, 94063